Form 4: Oramed CSO Sells Shares for Tax Obligations

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, disposed of 435,084 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Miriam Kidron, Chief Scientific Officer and Director of Oramed Pharmaceuticals Inc. (ORMP), reported a disposition of common stock.
• On March 30, 2026, 435,084 shares of common stock were disposed of.
• The disposition was made to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were valued at $3.31 per share, which was the closing price on the day immediately prior to the vesting date.
• Following this transaction, Miriam Kidron beneficially owns 1,133,138 shares of Oramed Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction related to equity compensation and does not signal any change in the company's fundamentals or management's confidence.

Positives

• The transaction is a routine, non-discretionary event related to equity compensation, indicating the vesting of previously granted Restricted Stock Units.

Negatives

• The disposition reduces the direct beneficial ownership of common stock by a key insider, though it is not a discretionary sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing non-discretionary sales for tax withholding purposes are common and routine for executives and directors receiving equity compensation. These transactions are a standard part of managing RSU vesting and typically do not reflect a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: The transaction represents a minor, routine reduction in insider ownership, which is a common occurrence with equity compensation vesting. It is unlikely to have a significant impact on shareholder sentiment or company valuation.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting. It does not provide new information regarding the company's operational performance, financial health, or strategic direction. Therefore, a seasoned investor or institution would likely maintain their current position, as this event does not warrant a change in investment thesis.

Keywords

Oramed Pharmaceuticals, ORMP, Form 4, Insider Transaction, Stock Sale, RSU, Restricted Stock Units, Tax Withholding, Miriam Kidron, Chief Scientific Officer